share_log

RBC Capital Upgrades Regeneron Pharmaceuticals to Outperform, Announces $1076 Price Target

Benzinga ·  Jan 12 06:45

RBC Capital analyst Brian Abrahams upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Sector Perform to Outperform and announces $1076 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment